Background: In recent years, an increasing number of auto-antibodies (AB) have been detected in the CSF and serum of patients with new onset epilepsy. Some of these patients develop convulsive or nonconvulsive status epilepticus (AB-SE), necessitating intensive medical care and administration of multiple antiepileptic and immunomodulatory treatments of uncertain effectiveness. Objectives: In this retrospective multicenter survey we aimed to determine the spectrum of gravity, the duration and the prognosis of the disorder. In addition, we sought to identify the antibodies associated with this condition, as well as determine whether there is a most effective treatment regime. Methods: 12 European Neurology University Clinics, with extensive experience in the treatment of SE patients, were sent a detailed questionnaire regarding symptoms and treatment of AB-SE patients. Seven centers responded positively, providing a total of 13 patients above the age of 16. Results: AB-SE affects mainly women (12/13, 92%) with a variable age at onset (17–69 years, median: 25 years). The duration of the disease is also variable (10 days to 12 years, median: 2 months). Only the 3 oldest patients died (55–69 years). Most patients were diagnosed with anti NMDAR encephalitis (8/13) and had oligoclonal bands in the CSF (9/13). No specific treatment regimen (antiepileptic, immunomodulatory) was found to be clearly superior. Most of the surviving 10 patients (77%) recovered completely or nearly so within 2 years of index poststatus. Conclusion: AB-SE is a severe but potentially reversible condition. Long duration does not seem to imply fatal outcome; however, age older than 50 years at time of onset appears to be a risk factor for death. There was no evidence for an optimal antiepileptic or immunomodulatory treatment. A prospective multicenter study is warranted in order to stratify the optimal treatment algorithm, determine clear risk factors of unfavorable outcome and long-term prognosis.

Keywords:
Status epilepticus, Autoimmune encephalitis, Antiepileptics, Immunomodulatory treatment, Patient outcome
1.
Palace J, Lang B: Epilepsy: an autoimmune disease? J Neurol Neurosurg Psychiatry 2000;69:711–714.
2.
McKnight K, Jiang Y, Hart Y, et al: Serum antibodies in epilepsy and seizure-associated disorders. Neurology 2005;65:1730–1736.
3.
Vincent A, Irani SR, Lang B: The growing recognition of immunotherapy-responsive seizure disorders with autoantibodies to specific neuronal proteins. Curr Opin Neurol 2010;23:144–150.
4.
Dalmau J: Status epilepticus due to paraneoplastic and nonparaneoplastic encephalitides. Epilepsia 2009;50(suppl 12):58–60.
5.
Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R, et al: Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010;30:5866–5875.
6.
Manto MU, Laute MA, Aguera M, Rogemond V, Pandolfo M, Honnorat J: Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol 2007;61:544–551.
7.
Nociti V: Refractory generalized seizures and cerebellar ataxia associated with anti-GAD antibodies responsive to immunosuppressive treatment. Eur J Neurol 2010;17:e5.
8.
Kanter IC, Huttner HB, Staykov D, Biermann T, Struffert T, Kerling F, et al: Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus. Epilepsia 2008;49:914–920.
9.
Suleiman J, Brenner T, Gill D, Brilot F, Antony J, Vincent A, et al: VGKC antibodies in pediatric encephalitis presenting with status epilepticus. Neurology 2011;76:1252–1255.
10.
Grujic J, Bien CG, Pollo C, Rossetti AO: Vagus nerve stimulator treatment in adult-onset Rasmussen’s encephalitis. Epilepsy Behav 2011;20:123–125.
11.
Maeder-Ingvar M, Prior JO, Irani SR, Rey V, Vincent A, Rossetti AO: FDG-PET hyperactivity in basal ganglia correlating with clinical course in anti-NDMA-R antibodies encephalitis. J Neurol Neurosurg Psychiatry 2011;82:235–6.
12.
Voskuhl R: Sex differences in autoimmune diseases. Biol Sex Differ 2011;2:1.
13.
Dalmau J: Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091–8.
14.
Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63–74.
15.
DeLorenzo RJ, Hauser WA, Towne AR, Boggs JG, Pellock JM, Penberthy L, Garnett L, Fortner CA, Ko D: A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996;46:1029–1035.
16.
Rossetti AO, Hurwitz S, Logroscino G, Bromfield EB: Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation. J Neurol Neurosurg Psychiatry 2006;77:611–615.
17.
Prüss H, Dalmau J, Harms L, Höltje M, Ahnert-Hilger G, Borowski K, Stoecker W, Wandinger KP: Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology 2010;75:1735–1739.
18.
Davies G, Irani SR, Coltart C, Ingle G, Amin Y, Taylor C, Radcliffe J, Hirsch NP, Howard RS, Vincent A, Kullmann DM: Anti-N-methyl-d-aspartate receptor antibodies: a potentially treatable cause of encephalitis in the intensive care unit. Crit Care Med 2010;38:679–682.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.